论文部分内容阅读
目的:探讨结外NK/T细胞淋巴瘤(鼻型)(ENKTCL)可能的预后因素。方法:回顾性分析31例ENKTCL患者的临床资料,对临床特点、可能的预后相关实验室指标及治疗模式行预后单因素分析。结果:治疗前ECOG体能状态评分0~1的患者占94%,Ann ArborⅠ/Ⅱ期患者占42%,国际预后指数低危患者占39%,低蛋白血症患者占29%。近期疗效完全缓解率48%(13/27例),中位生存时间28个月。1年、2年和3年的总生存率分别为78%、59%和48%。单因素分析显示治疗前白蛋白水平、治疗模式及近期疗效与ENKTCL患者的预后有关。结论:治疗前白蛋白水平、治疗模式及近期疗效可作为ENKTCL预后的参考因素。
Objective: To investigate the possible prognostic factors of extranodal NK / T cell lymphoma (nasal type) (ENKTCL). Methods: The clinical data of 31 patients with ENKTCL were retrospectively analyzed. The clinical characteristics, possible laboratory parameters related to prognosis, and univariate analysis of the treatment modalities were performed. Results: 94% of patients with ECOG scores of 0 ~ 1 before treatment, 42% of patients with Ann Arbor Ⅰ / Ⅱ, 39% of patients with low risk of international prognosis, and 29% of patients with hypoproteinemia. The immediate effect of complete remission rate was 48% (13/27 cases), the median survival time of 28 months. The overall survival rates at 1 year, 2 years and 3 years were 78%, 59% and 48%, respectively. Univariate analysis showed that pre-treatment albumin levels, treatment modalities and short-term efficacy were related to the prognosis of ENKTCL patients. Conclusion: Pre-treatment albumin levels, treatment modalities and short-term efficacy can be used as a reference for ENKTCL prognosis.